Related Experiment Videos
Medulloblastoma: WHO 2021 and Beyond
Jennifer A Cotter1, Cynthia Hawkins2,3,4
1Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
Summary
Medulloblastoma classification was updated in 2016 to include molecular and genetic data. This allows for a more precise diagnosis based on tumor biology, improving patient care.
Area of Science:
- Neuro-oncology
- Molecular Pathology
- Genomics
Background:
- Medulloblastoma classification was updated in 2016.
- The update incorporated molecular biology, genomics, and clinical behavior data.
- For the first time, medulloblastomas were classified using both molecular and histologic characteristics.
Purpose of the Study:
- Review the most recent medulloblastoma classification update.
- Provide a practical approach to molecular and immunohistochemical testing.
- Demonstrate using molecular genetic findings for integrated diagnosis.
Main Methods:
- Review of updated medulloblastoma classification guidelines.
- Description of immunohistochemical and molecular testing strategies.
- Analysis of key molecular genetic findings.
Main Results:
- Genetically-defined medulloblastoma categories include WNT-activated, SHH-activated TP53 wildtype, SHH-activated TP53-mutant, and non-WNT/non-SHH.
- The updated classification integrates molecular and histologic features.
- Practical testing approaches facilitate diagnosis.
Conclusions:
- The 2016 medulloblastoma classification provides a framework for integrated diagnosis.
- Molecular and genetic testing are crucial for accurate subtyping.
- This approach aids in understanding tumor biology and clinical behavior.